ICER takes on Aetion’s RWE platform

By Jenni Spinner

- Last updated on GMT

ICER takes on Aetion’s RWE platform

Related tags Real-world evidence Real-world data

The ICER plans to harness the company’s technology to expand use of real-world evidence.

As a health technology assessment (HTA) organization, ICER works to evaluate how emerging medical interventions serve to improve patients’ lives. It also suggests benchmark prices that fall in line with an intervention’s benefit to patients and the overall healthcare system.

In its 2020 Value Assessment Framework, ICER outlined plans to generate RWE for assessments. Additionally, the group recently laid the groundwork for harnessing RWE in two-year reevaluations of US FDA-approved drugs, under accelerated approval routes.

Broad health industry benefits

An Aetion spokesperson told Outsourcing-Pharma that the use of RWE benefits people across the healthcare spectrum.

It furthers ICER’s mission of catalyzing a movement toward fair pricing, fair access, and future innovation across the entire US health system​,” they said.

Pamela Bradt, chief scientific officer for ICER, said analytics from Aetion’s Evidence Platform will empower the organization to more efficiently gather evidence for its review process.

“Through this partnership, we aim to set new standards for how RWE can better inform the consequential decisions that biopharma manufacturers, insurers, and other stakeholders make every single day around drug pricing and patient access,”​ Bradt said.

Sharing information

According to Aetion, protocols developed via the partnership with ICER will be included in assessments that ICER shares publicly. The open sharing of information, in turn, will benefit other stakeholders in the industry.

Integrating RWE into ICER’s assessments will advance how we as a health care industry—and a society—determine value​,” said Carolyn Magill, CEO of Aetion.

Aetion has partnered with several organizations and companies to promote use of RWE. In August 2018, Harvard Medical School and Brigham’s Women’s Hospital​ tapped the Evidence Platform to support their Reproducible Evidence Practices to Enhance and Achieve Transparency (REPEAT) program.

Additionally, in October 2019, McKesson and Aetion​ announced a collaboration to advance the use of RWE in cancer research.

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more